In silico toxicology: Simulating interaction thresholds for human exposure to mixtures of trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane

Environmental Health Perspectives

Volumn 110, Issue 10, 2002, Pages 1031-1039

  Dobrev, Ivan D ^a   Andersen, Melvin E ^a   Yang, Raymond S H ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Chemical mixtures; Computational toxicology; in silico toxicology; Interaction thresholds; Metabolic interaction; Methylchloroform; Occupational exposure; PBPK modeling; Tetrachloroethylene; Trichloroethylene

Indexed keywords

1,1,1 TRICHLOROETHANE; GLUTATHIONE; ORGANIC SOLVENT; TETRACHLOROETHYLENE; TRICHLOROETHYLENE;

ARTICLE; BLOOD LEVEL; CALIBRATION; CARCINOGENICITY; COMPUTER SIMULATION; CONTROLLED STUDY; GLUTATHIONE METABOLISM; METABOLITE; NEPHROTOXICITY; NONLINEAR SYSTEM; OCCUPATIONAL EXPOSURE; OCCUPATIONAL TOXICOLOGY; PREDICTION; PRIORITY JOURNAL; PUBLISHING; RISK ASSESSMENT; TOXICOKINETICS; TOXICOLOGICAL PARAMETERS;

ANIMALIA;

EID: 0036797822     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.021101031     Document Type: Article

References (51)

1. ACGIH. 2000. 2000 TLVs and BEls: Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH:ACGIH.
2. Anders MW, Dekant W. 1998. Glutathione-dependent bioactivation of haloalkanes. Ann Rev Pharmacol Toxicol 38:501-537.
3. Andersen ME. 1981. A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: Analysis at steady state. Toxicol Appl Pharmacol 60:509-526.
4. Andersen ME, Gargas ML, Clewell HJ III, Severyn KM. 1987. Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylene in vivo using gas uptake methods. Toxicol Appl Pharmacol 89:149-157.
5. ATSDR. 1997. CERCLA Priority List of Hazardous Substances that will be the Subject of Toxicological Profiles (Support Document). Atlanta, GA:Agency for Toxic Substances and Disease Registry.
6. Barton HA, Clewell HJ. 2000. Evaluating non-cancer effects of trichloroethylene: dosimetry, mode of action, and risk assessment. Environ Health Perspect 108(suppl 2):323-334.
7. Barton HA, Creech JR, Godin CS, Randall GM, Seckel CS. 1995. Chloroethylene mixtures: pharmacokinetic modeling and in vitro metabolism of vinyl chloride, trichloroethylene, and trans-1,2-dichloroethylene in rat. Toxicol Appl Pharmacol 130:237-247.
8. Barton HA, Das S. 1996. Alternatives for a risk assessment on chronic non-cancer effects from oral exposure to trichloroethylene. Reg Toxicol and Pharmacol 24:269-285.
9. Bernauer U, Birner G, Dekant W, Henschler D. 1996. Biotransformation of trichloroethylene: dose-dependent excretion of 2,2,2-trichlorometabolites and mercapturic acids in rats and humans after inhalation. Arch Toxicol 70:338-346.
10. Bloemen LJ, Monster AC, Kezic S, Commandeur JNM, Veulemans H, Vermeulen NPE, et al. 2001. Study on the cytochrome P-450- and glutathione-dependent biotransformation of trichloroethylene in humans. Int Arch Occup Environ Health 74:102-108.
11. Bogen KT, Gold LS. 1997. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end-points. Reg Toxicol Pharmacol 25:26-42.
12. Bruening T, Bolt HM. 2000. Renal toxicity and carcinogenicity of trichloroethylene: key results, mechanisms, and controversies. Crit Rev Toxicol 30:253-285.
13. Bull RJ. 2000. Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetate and dichloroacetate. Environ Health Perspect 108:241-259.
14. Clewell HJ, Gentry PR, Covington TR, Gearhart JM. 2000. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ Health Perspect 108:283-305.
15. Dobrev ID, Andersen ME, Yang RSH. 2001. Assessing interactions thresholds for trichloroethylene in combination with tetrachloroethylene and 1,1,1-trichloroethane using gas uptake studies and PBPK modeling. Arch Toxicol 75:134-144.
16. Droz P, Wu M, Cumberland W. 1989. Variability in biological monitoring of solvent exposure. I. Application of a population physiological model. Br J Ind Med 46:547-548.
17. El-Masri HA, Constan AA, Ramsdell HS, Yang RSH. 1996a. Physiologically based pharmacokinetic modeling of an interaction threshold between trichloroethylene and 1,1-dichloroethylene in Fischer 344 rats. Toxicol Appl Pharmacol 141:124-132.
18. El-Masri HA, Tessari JD, Yang RSH. 1996b. Extrapolation of an interaction threshold for the joint toxicity of trichloroethylene and 1,1-dichloroethylene: utilization of a PBPK model. Arch Toxicol 70:527-539.
19. El-Masri HA, Thomas RS, Sabados GR, Phillips JK, Constan AA, Benjamin SA, et al. 1996c. Physiologically based pharmacokinetic/pharmacodynamic modeling of the toxicologic interaction between carbon tetrachloride and kepone. Arch Toxicol 70:704-713.
20. Fernandez J, Guberan E, Caperos J. 1976. Experimental human exposure to tetrachloroethylene vapor and elimination in breath after inhalation. Am Ind Hyg Assoc J 37:143-150.
21. Fisher JW. 2000. Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites. Environ Health Perspect 108:265-273.
22. Fisher JW, Mahle D, Abbas R. 1998. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. Toxicol Appl Pharmacol 152:339-359.
23. Gargas ML, Andersen ME, Clewell HJ III. 1986. A physiologically based simulation approach for determining metabolic constants from gas uptake data. Toxicol Appl Pharmacol 86:341-352.
24. Gargas ML, Clewell HJ III, Andersen ME. 1990. Gas uptake inhalation techniques and the rates of metabolism of chloromethanes, chloroethanes, and chloroethylenes in the rat. Inhal Toxicol 2:295-319.
25. Green T, Dow J, Ellis MK, Foster JR, Odum J. 1997. The role of glutathione conjugation in the development of kidney tumors in rats exposed to trichloroethylene. Chem Biol Interact 105:99-117.
26. Haddad S, Beliveau M, Tardif R, Krishnan K. 2001. A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures. Toxicol Sciences 63:125-131.
27. Henschler D, Vamvakas S, Lammert M, Dekant W, Kraus B, et al. 1995. Increased incidence of renal cell cancer tumors in a cohort of cardboard workers exposed to trichloroethylene. Arch Toxicol 69:291-299.
28. IARC. 19991 1,1,1-Trichloroethane. IARC Monogr Eval Carcinog Risks Hum 71:881-903.
29. Jang J-Y, Droz PO, Berode M. 1997. Ethnic differences in biological monitoring of several organic solvents. I. Human exposure experiment. Int Arch Environ Health 69:343-349.
30. Jang JY, Droz PO, Chung HK. 1999a. Uncertainties in physiologically based pharmacokinetic models caused by several input parameters. Int Arch Occup Environ Health 72:247-254.
31. Jang JY, Droz PO, Kim S. 2001. Biological monitoring of workers exposed to ethylbenzene and co-exposed to xylene. Int Arch Occup Environ Health 74:31-37
32. Jang JY, Lee SY, Kim JI, Park JB, Lee KJ, Chung HK. 1999b. Application of bilogical monitoring to the quantitative exposure assessment for neuropsychological effects by chronic exposure to organic solvents. Int Arch Occup Environ Health 72:107-114.
33. Krishnan L, Andersen ME, Clewell HJ, Yang RSH. 1994a. Physiologically based pharmacokinetic modeling of chemical mixtures. In: Toxicolgy of Chemical Mioxtures: Case Studies, Mechanism, and Novel Approaches (Yang RSH, ed). San Diego, CA:Academic Press;399-437.
34. Krishnan K, Clewell HJ III, Andersen ME. 1994b. Physiologically based pharmacokinetic analysis of simple mixtures Environ Health Perspect 102(suppl 9):151-155.
35. Lash LH, Fisher JW, Lipscomb JC, Parker JC. 2000. Metabolism pof trichloroethylene. Environ Health Perspect 108:177-200.
36. Monster AC. 1979. Difference in uptake, elimination, and metabolism in exposure to trichloroethylene, 1,1,1-trichloroethane and tetrachloroethylene. Int Arch Occup Environ Health 42:311-317.
37. Monster AC, Boersma G, Steenweg H. 1979. Kinetics of tetrachloroethane in volounteers: influence of exposure concentration and workload. Int Arch Occup Environ Health 42:303-309.
38. Muntaz MM, Rosa CTD, Groten J, Feron VJ, Hansen H, Durkin PR. 1998. Estimation of toxicity of chemical mixtures through modeling of chemical interactions. Environ Health Perspect 106:1353-1360.
39. Nolan RJ, Freshour NL, Rick DL, McCarty L, Saunders JH. 1984. Kinetics and metabolism of inhaled methyl chloroform (1,1,1-trichloroethane) in male volounteers. Fund Appl Toxicol 4:654-662.
40. Ou YC, Connelly, RB, Thomas RS, Xu Y, Andersen ME, Chubb L, et al. 2001. A clonal growth model: time-course simulations of liver feel growth following penta- or hexa-chlorobenzene treatment in a medium-term bioassay. Cancer Res. 61:1879-1889.
41. Ou YC, Connolly RB, Lapidot SA, Thomas RS, Gustafson DL, Long ME, et al. Unpublished data.
42. Pelekis M, Krishnan K. 1997. Assessing the relevance of rodent data on chemical interactions for health risk assessment purposes: a case study with dichloromethane-toluene mixture. Reg Toxicol Pharmacol l25:79-86.
43. Reitz RH, Gargas ML, Mendrala AL, Schumann AM. 1996. In vivo and in vitro studies of perchloroethylene metabolism for physiologically based pharmacokinetic modeling in rats, mice, and humans. Toxicol Appl Pharmacol 136:289-306.
44. Reitz RH, McDougal JN, Nolan RJ, Schumann AM. 1988. Physiologically based pharmacokinetic modeling with methylchloroform: implications for interspecies, high dose/low dose, and dose route extrapolations. Toxicol Appl Pharmacol 95:185-199.
45. Tardif R, Charest-Tardif G. 1999. The importance of measured end-points in demonstrating the occurrence of interations: A case study with methylchloroform and m-xylene. Toxicol Sciences 49:312-317.
46. Tardif R, Lapare S, Charest-Tardif G, Brodeur J, Krishnan K. 1995. Physiologically-based pharmacokinetic modeling of a mixture of toluene and xylene in humans. Risk Anal 15:335-342.
47. Tardif R, Lapare S, Krishnan K, Brodeur K. 1993. Physiologically based modeling of the toxicokinetic interation between toluene and m-xylene in the rat. Toxicol Appl Pharmacol 120:266-273.
48. Thomas RS, Bigelow PL, Keefe TJ, Yang RSH. 1996a. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation. Am Ind Hyg Assoc J 57:23-32.
49. Thomas RS, Yang RSH, Morgan DG, Moorman MP, Kermani HRS, Sloane RA et al. 1996b. PBPK modeling/Monte Carlo simulation of methylene chloride kinetic changes in mice in relation to age and acute, subchronic, and chronic inhalation exposure. Environ Health Perspect 104:858-865.
50. Ward RC, Travis CC, Hetrick DM, Andersen ME, Gargas ML 1988. Pharmacokinetics of tetrachloroethylene. Toxicol Appl Pharmacol 93:108-117.
51. Wu C, Schaum J. 2000. Exposure assessment of trichloroethylene. Environ Health Perspect 108:359-363.